Volume 19, Number 3—March 2013
Research
Effects of Vaccine Program against Pandemic Influenza A(H1N1) Virus, United States, 2009–2010
Table 6
Subgroup | Base case estimate (range)† | Scenario |
|||
---|---|---|---|---|---|
1: even distribution over time (range)‡ | 2: distribution based on population proportion (range)§ | 3: 2008 distribution (range)¶ | 4: ACIP priority subgroups (range)# | ||
6 mo–9 y | 81,518 (52,081–100,349) | 131,170 (90,932–164,352) | 57,511 (39,869–72,060) | 65,093 (45,125–81,559) | 186,041 (128,970–233,103) |
10–24 y (10–17 all, 18–24 NP) | 300,724 (212,953–420,991) | 279,715 (196,606–392,577) | 310,656 (218,355–436,003) | 249,981 (175,708–350,847) | 396,725 (278,851–556,801) |
Pregnant, 18–64 y | 71,601 (53,084–97,884) | 44,486 (31,726–60,936) | 30,506 (21,756–41,787) | 14,809 (10,561–20,285) | 63,096 (44,998–86,427) |
HR, 25–64 y | 164,958 (116,575–228,593) | 168,521 (119,243–233,197) | 183,417 (129,784–253,810) | 73,157 (51,765–101,234) | 239,017 (169,125–330,749) |
HCW, 25–64 y | 123,427 (87,287–177,144) | 100,229 (69,407–144,610) | 82,764 (57,313–119,413) | 41,099 (28,460–59,297) | 142,157 (98,441–205,104) |
Contact with <6 mo | 29,063 (19,904–43,129) | 28,861 (19,686–42,794) | 37,583 (25,634–55,726) | 151,525 (103,351–224,675) | 40,935 (27,920–60,696) |
25–64 y (all others) | 163,327 (107,305–248,548) | 197,372 (133,316–297,625) | 366,354 (247,455–552,439) | 278,226 (187,928–419,547) | 0 |
>65 y |
94,538
(63,719–142,293) |
99,116
(67,121–148,741) |
103,402
(70,023–155,172) |
197,547
(133,778–296,454) |
0 |
Total |
1,029,157
(712,908–1,458,930) |
1,049,470
(728,037–1,484,834) |
1,172,194
(810,188–1,686,411) |
1,071,437
(736,676–1,553,899) |
1,067,971 (748,306–1,472,881) |
Assumed % distribution by week** |
|||||
6 mo–9 y, 1st dose†† | 20 | 20 | 9 | 10 | 28 |
6 mo–9 y, 2nd dose | 10 | 10 | 4 | 5 | 14 |
10–24 y (10–17 all, 18–24 NP) | 18 | 18 | 20 | 16 | 25 |
Pregnant, 18–64 y | 3 | 3 | 2 | 1 | 4 |
HR, 25–64 y | 10 | 10 | 11 | 5 | 15 |
HCW, 25–64 y | 7 | 7 | 6 | 3 | 10 |
Contact with <6 mo | 2 | 2 | 3 | 12 | 3 |
25–64 y (all others) | 17 | 17 | 32 | 24 | 0 |
>65 y | 12 | 12 | 13 | 24 | 0 |
*Data reflect calculations made in scenarios 1 –4. ACIP, Advisory Committee on Immunization Practices; NP, not pregnant; HR, high risk; HCW, health care worker; contact, household contacts and caregivers of children <6 mo of age.
†Total number of doses administered to each population subgroup (Table 2).
‡For each population subgroup, this scenario assumes that the group received the same proportion of the total number of doses; the proportions were applied to the total number of doses administered each week (Table 2, Appendix).
§ It was assumed that the distribution of vaccines was proportional to the population.
¶Distribution of vaccine was based on estimates of estimated 2008 seasonal vaccine uptake (17,38).
#Distribution of vaccine was based exclusively on ACIP priority groupings. The proportion of doses administered was based on the proportion of doses administered to persons in each of the subgroups during the A(H1N1)pdm09 virus vaccination program, while excluding the non ACIP subgroups.
**In scenarios 1–4, the epidemiologic curve was based on the estimated A(H1N1)pdm09 vaccination curve, for which no vaccination program was assumed (Figure 1). We also assumed that the total number of vaccines administered each week remained exactly the same as outlined in Table 2, Appendix.
††For scenarios 1–4, we assumed that the 6 mo– 9 y age group required 2 doses and that a 4 wk delay was required between the first and second dose. We also assumed that no children 6 mo–9 years of age could have received their second dose until the fifth week of the vaccination program. Therefore, any doses during the first 4 wk that would have been proportioned as a second dose were added as a first dose.
References
- Department of Homeland Security. Press briefing on swine influenza with Department of Homeland Security and Counterterrorism, Centers for Disease Control and Prevention, and the White House. Washington: Office of the Press Secretary; 2009 April 26 [cited 2011 Mar 30]. http://www.whitehouse.gov/the_press_office/Press-Briefing-On-Swine-Influenza-4/26/09
- Shrestha SS, Swerdlow DL, Borse RH, Prabhu VS, Finelli L, Atkins CY, Estimating the burden of 2009 pandemic influenza A (H1N1) in the United States (April 2009–April 2010). Clin Infect Dis. 2011;52(Suppl 1):S75–82 . DOIPubMedGoogle Scholar
- US Food and Drug Administration. FDA approves vaccines for 2009 H1N1 influenza virus—approval provides important tool to fight pandemic. 2009 Sep 15 [cited 2010 Mar 20]. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2009/ucm182399.htm
- Centers for Disease Control and Prevention. Interim results: state-specific influenza A (H1N1) 2009 monovalent vaccination coverage—United States, October 2009–January 2010. MMWR Morb Mortal Wkly Rep. 2010;59:363–8 .PubMedGoogle Scholar
- Schuchat A, Bell BP, Redd SC. The science behind preparing and responding to pandemic influenza: the lessons and limits of science. Clin Infect Dis. 2011;52(Suppl 1):S8–12. DOIPubMedGoogle Scholar
- Sypsa V, Hatzakis A. School closure is currently the main strategy to mitigate influenza A(H1N1)v: a modeling study. Euro Surveill. 2009;14:pii19240 .PubMedGoogle Scholar
- Partridge J, Kieny MP. World Health Organization H1N1 influenza vaccine Task Force. Global production of seasonal and pandemic (H1N1) influenza vaccines in 2009–2010 and comparison with previous estimates and global action plan targets. Vaccine. 2010;28:4709–12 . DOIPubMedGoogle Scholar
- US Food and Drug Administration, Vaccines and Related Biological Products Advisory Committee. Transcript of July 23, 2009 VRBPAC meeting. Regulatory consideration regarding the use of novel influenza A (H1N1) virus vaccines. 2010 [cited 2011 Mar 30]. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/VaccinesandRelatedBiologicalProductsAdvisoryCommittee/UCM172424.pdf
- Centers for Disease Control and Prevention [Internet]. Influenza vaccination coverage, 2009–10 influenza season. 2011 [updated 2012 Sep 26; cited 2011 Mar 30]. http://www.cdc.gov/flu/fluvaxview/0910season.htm
- Singleton JA. H1N1 vaccination coverage. Advisory Committee on Immunization Practices February 2010 meeting; presentation slides; 2010 Feb 25–26 meeting. Atlanta, Georgia. Atlanta: Centers for Disease Control and Prevention [cited 2011 Mar 30]. http://www.cdc.gov/vaccines/acip/meetings/meetings-info.html#slides
- Centers for Disease Control and Prevention. Final estimates for 2009–10 seasonal influenza and influenza A (H1N1) 2009 monovalent vaccination coverage—United States, August 2009 through May, 2010 [cited 2011 Feb 1]. http://www.cdc.gov/flu/professionals/vaccination/coverage_0910estimates.htm
- Veguilla V, Hancock K, Schiffer J, Gargiullo P, Lu X, Aranio D, Sensitivity and specificity of serologic assays for the detection of human infection with 2009 pandemic H1N1 virus in U.S. populations. J Clin Microbiol. 2011;49:2210–5. DOIPubMedGoogle Scholar
- Centers for Disease Control and Prevention. Updated CDC estimates of 2009 H1N1 influenza cases, hospitalizations and deaths in the United States, April 2009–April 10, 2010 [cited 2011 Mar 30]. http://www.cdc.gov/h1n1flu/pdf/CDC_2009_H1N1_Est_PDF_May_4_10_fulltext.pdf
- Singleton JA. Who got H1N1 vaccine? Findings from the U.S. 2009–2010 influenza vaccination surveillance systems. 44th National Immunization Conference. Atlanta, GA, USA, 2010 April 22 [cited 2011 Mar 30]. http://cdc.confex.com/cdc/nic2010/recordingredirect.cgi/id/6781
- Wortley P. H1N1 Influenza vaccination coverage by ACIP target groups, program implementation. 2010 [cited 2010 Apr 22]. www.immunizationmanagers.org/membership/Pascale.ppt
- Centers for Disease and Prevention. Interim results: influenza A (H1N1) 2009 monovalent and seasonal influenza vaccination coverage among health-care personnel—United States, August 2009–January 2010. MMWR Morb Mortal Wkly Rep. 2010;59:357–62 .PubMedGoogle Scholar
- Centers for Disease Control and Prevention. Projected influenza vaccination target population sizes, vaccination coverage and doses to be used during the 2008–09 season. 2008 [cited 2009 August 30]. http://www.cdc.gov/flu/professionals/vaccination/pdf/influenza_vaccine_target_populations.pdf
- Moro PL, Broder K, Zheteyeva Y, Revzina N, Tepper N, Kissin D, Adverse events following administration to pregnant women of influenza A (H1N1) 2009 monovalent vaccine reported to the Vaccine Adverse Event Reporting System. Am J Obstet Gynecol. 2011;205:473. DOIPubMedGoogle Scholar
- Jain S, Kamimoto L, Bramley AM, Schmitz AM, Benoit SR, Louie J, Hospitalized patients with 2009 H1N1 influenza in the United States, April–June 2009. N Engl J Med. 2009;361:1935–44 . DOIPubMedGoogle Scholar
- Reed C, Angulo FJ, Swerdlow DL, Lipsitch M, Meltzer MI, Jernigan DB, Estimates of the prevalence of pandemic (H1N1) 2009, United States, April–July 2009. Emerg Infect Dis. 2009;15:2004–7 .DOIPubMedGoogle Scholar
- Skarbinski J, Jain S, Bramley A, Lee EJ, Huang J, Kirschke D, Hospitalized patients with 2009 pandemic influenza A (H1N1) virus infection in the United States—September–October 2009. Clin Infect Dis. 2011;52(Suppl 1):S50–9. DOIPubMedGoogle Scholar
- Furlow CF, Singleton JA, Bardenheier B. Combining estimates of influenza vaccination coverage from the BRFSS 2009–2010 and the National 2009 H1N1 Flu Survey. Poster presented at: Annual Behavioral Risk Factor Surveillance System Conference; Atlanta, GA, USA; March 20–23, 2011.
- Centers for Disease Control and Prevention. Update on influenza A (H1N1) 2009 monovalent vaccines. MMWR Morb Mortal Wkly Rep. 2009;58:1100–1 .PubMedGoogle Scholar
- Wu J, Xu F, Lu L, Lu M, Miao L, Gao T, Safety and effectiveness of a 2009 H1N1 vaccine in Beijing. N Engl J Med. 2010;363:2416–23 . DOIPubMedGoogle Scholar
- Valenciano M, Kissling E, Cohen J-M, Oroszi B, Barret A-S, Rizzo C, Estimates of pandemic influenza vaccine effectiveness in Europe, 2009–2010: results of influenza monitoring vaccine effectiveness in Europe (I-MOVE) multicentre case-control study. PLoS Med. 2011;8:e1000388 . DOIPubMedGoogle Scholar
- Castilla J, Morán J, Martinez-Artola V. Fernández -Alonso M, Guevara M, Cenoz MG, et al. Effectiveness of the monovalent influenza A(H1N1)2009 vaccine in Navarre, Spain, 2009–2010: cohort and case control study. Vaccine. 2011;29:5919–24. DOIPubMedGoogle Scholar
- Wichmann O, Stocker P, Poggensee G, Altmann D, Walter D, Hellenbrand W, Pandemic influenza A(H1N1) 2009 breakthrough infections and estimates of vaccine effectiveness in Germany 2009–2010. Euro Surveill. 2010;15:pii19561 .PubMedGoogle Scholar
- Centers for Disease Control and Prevention. Interim results: influenza A (H1N1) 2009 monovalent vaccination coverage—United States, October-December 2009. MMWR Morb Mortal Wkly Rep. 2010;59:44–8 .PubMedGoogle Scholar
- Gurav YK, Pawar SD, Chadha MS, Potdar VA, Deshpande AS, Koratkar SS, Pandemic influenza A(H1N1) 2009 outbreak in a residential school at Panchgani, Maharashtra, India. Indian J Med Res. 2010;132:67–71 .PubMedGoogle Scholar
- Baker MG, Wilson N, Huang QS, Paine S, Lopez L, Bandaranayake D, Pandemic influenza A(H1N1)v in New Zealand: the experience from April to August 2009. Euro Surveill. 2009;14:pii19319 .PubMedGoogle Scholar
- Health Protection Agency. Pandemic (H1N1) 2009 in England: an overview of initial epidemiological findings and implications for the second wave. 2009 [cited 2011 Mar 30]. http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1258560552857
- von Kries R, Weiss S, Falkenhorst G, Wirth S, Kaiser P, Huppertz HI, Post-pandemic seroprevalence of pandemic influenza A (H1N1) 2009 infection (swine flu) among children <18 years in Germany. PLoS ONE. 2011;6:e23955 . DOIPubMedGoogle Scholar
- Kumar S, Fan J, Melzer-Lange M, Trost J, Havens PL, Willoughby RE, H1N1 hemagglutinin-inhibition seroprevalence in emergency department health care workers after the first wave of the 2009 influenza pandemic. Pediatr Emerg Care. 2011;27:804–7 . DOIPubMedGoogle Scholar
- Jackson ML, France AM, Hancock K, Lu X, Veguilla V, Sun H, Serologically confirmed household transmission of 2009 pandemic influenza A (H1N1) virus during the first pandemic wave—New York City, April–May 2009. Clin Infect Dis. 2011;53:455–62 . DOIPubMedGoogle Scholar
- Li T, Liu Y, Di B, Wang M, Shen J, Zhang Y, Epidemiological investigation of an outbreak of pandemic influenza A (H1N1) 2009 in a boarding school: serological analysis of 1570 cases. J Clin Virol. 2011;50:235–9 . DOIPubMedGoogle Scholar
- Carrat F, Vergu E, Ferguson NM, Lemaitre M, Cauchemez S, Leach S, Time lines of infection and disease in human influenza: a review of volunteer challenge studies. Am J Epidemiol. 2008;167:775–85. DOIPubMedGoogle Scholar
- Plennevaux E, Blatter M, Cornish MJ, Go K, Kirby D, Wali M, Influenza A (H1N1) 2009 two-dose immunization of US children: an observer-blinded, randomized, placebo-controlled trial. Vaccine. 2011;29:1569–75 . DOIPubMedGoogle Scholar
- Stöhr K, Esveld M. Will vaccines be available for the next influenza pandemic? Science. 2004;306:2195–6. DOIPubMedGoogle Scholar
- Moro PL, Broder K, Zheteyeva Y, Revzina N, Tepper N, Kissin D, Adverse events following administration to pregnant women of influenza A (H1N1) 2009 monovalent vaccine reported to the Vaccine Adverse Event Reporting System. Am J Obstet Gynecol. 2011;205:473.e1–9.
- Monto AS, Ohmit SE, Petrie JG, Johnson E, Truscon R, Teich E, Comparative efficacy of inactivated and live attenuated influenza vaccines. N Engl J Med. 2009;361:1260–7. DOIPubMedGoogle Scholar
1Current affiliation: Merck & Co., Inc., Lansdale, Pennsylvania, USA.